SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Andersson Lars A H)
 

Sökning: WFRF:(Andersson Lars A H) > Efficacy and safety...

  • Hijazi, ZiadUppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi (författare)

Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • MOSBY-ELSEVIER,2018
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-352697
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-352697URI
  • https://doi.org/10.1016/j.ahj.2017.10.015DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Renal function may decline over time, and the efficacy and safety of dabigatran in atrial fibrillation (AF) in relation to renal function changes are unknown.& para;& para;Methods: The RE-LY trial randomized 18,113 patients with AF to 2 doses of dabigatran or warfarin for stroke prevention. Serial creatinine measurements were available in 16,988 patients. The relations between treatment, outcomes, and renal function (Cockcroft-Gault) were investigated using Cox-regression (1) with renal function as a time-dependent covariate and (2) according to worsening renal function (WRF) during follow-up, predefined as a decline in estimated glomerular filtration rate >20% from baseline.& para;& para;Results: During a median follow-up of 1.8 years, 4,106 (24.2%) participants were observed to have WRF, and 12,882 (75.8%) had stable renal function. The risks of all-cause mortality and major bleeding were higher in patients with WRF versus those with stable renal function (hazard ratio [95% CI]: 2.17 [1.81-2.59] and 1.43 [1.19-1.71]. respectively; both P < .0005). The efficacy and safety of dabigatran versus warfarin were similar irrespective of renal function changes over time (interaction P values >= .13 in both models). Dabigatran 110 mg showed a greater relative risk reduction of major bleeding in patients with normal renal function (estimated glomerular filtration rate >80 mL/min) during follow-up (interaction P= .026).& para;& para;Conclusions: In AF, WRF was associated with a higher risk of death and major bleeding. The efficacy and safety profile of dabigatran compared with warfarin was similar irrespective of renal function changes over time. Dabigatran 110 mg showed a greater relative risk reduction of major bleeding in patients with normal renal function during follow-up.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Hohnloser, Stefan H.Goethe Univ Frankfurt, Dept Cardiol, Frankfurt, Germany (författare)
  • Oldgren, Jonas,1964-Uppsala universitet,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)jonaoldg (författare)
  • Andersson, UlrikaUppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)ulran224 (författare)
  • Connolly, Stuart J.Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Eikelboom, John W.Populat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Ezekowitz, Michael D.Thomas Jefferson Med Coll, Wynnewood, PA USA;Heart Ctr, Wynnewood, PA USA (författare)
  • Reilly, Paul A.Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA (författare)
  • Yusuf, SalimPopulat Hlth Res Inst, Hamilton, ON, Canada (författare)
  • Wallentin, Lars,1943-Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)larswall (författare)
  • Uppsala universitetUppsala kliniska forskningscentrum (UCR) (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:American Heart Journal: MOSBY-ELSEVIER198, s. 169-1770002-87031097-6744

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy